Related Experiment Video
Updated: Jul 17, 2026
Identifying Protein-protein Interaction Sites Using Peptide Arrays
Published on: November 18, 2014
Targeting APL fusion proteins by peptide interference
1Department of Developmental and Molecular Biology and Medical Oncology, Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY 10461, USA. amelnick@aecom.yu.edu
Abstract:
A significant barrier to experimental therapeutics is the ability to identify and specifically target oncogenic proteins involved in the molecular pathogenesis of disease. In acute promyelocytic leukemia (APL), aberrant transcription factors and their associated machinery play a central role in mediating the malignant phenotype. The mechanism of action of APL chimeric fusion proteins involves their ability to either self-associate or interact with different partner proteins. Thus, targeting protein-protein interactions could have a significant impact in blocking the activity of APL oncoproteins. As therapeutic targets, the interface between interacting proteins may not always be amenable to highly specific small molecule blockade. In contrast, peptides are well-suited to this purpose and can be reliably delivered when fused to cell-permeable peptide domains. Therapeutic peptides can be designed to directly target APL fusion proteins, their downstream effectors, or other potentially synergistic oncogenic mechanisms of importance in APL blasts. In addition to serving as potential therapeutic agents, such reagents could serve as powerful reagents to dissect the molecular pathogenesis of APL.
Insights
Targeting protein-protein interactions with therapeutic peptides offers a novel strategy for acute promyelocytic leukemia (APL). This approach can block oncogenic APL fusion proteins and dissect disease mechanisms.
Area of Science:
- Molecular Biology
- Oncology
- Drug Discovery
Background:
- Identifying and targeting oncogenic proteins is crucial for developing effective experimental therapeutics.
- Aberrant transcription factors drive the malignant phenotype in acute promyelocytic leukemia (APL) by mediating protein-protein interactions.
- Targeting these protein-protein interactions presents a promising strategy to inhibit APL oncoproteins.
Purpose of the Study:
- To explore the potential of therapeutic peptides in targeting oncogenic protein-protein interactions in APL.
- To investigate peptides as a viable alternative to small molecules for blocking protein interfaces.
- To highlight the dual role of therapeutic peptides as agents for treatment and research tools.
Main Methods:
- Designing therapeutic peptides to target APL fusion proteins or their interacting partners.
- Utilizing cell-permeable peptide domains for reliable delivery of therapeutic peptides.
- Investigating peptide-mediated blockade of oncogenic protein-protein interactions.
Main Results:
- Protein-protein interactions are central to APL pathogenesis and represent viable therapeutic targets.
- Therapeutic peptides can be designed to specifically target these interactions.
- Peptides offer advantages over small molecules for targeting protein interfaces.
Conclusions:
- Therapeutic peptides show significant promise for treating APL by disrupting oncogenic protein-protein interactions.
- Peptide-based therapeutics can be engineered for targeted delivery and efficacy.
- These peptides can also serve as valuable tools for understanding APL molecular pathogenesis.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:24Tagging and Fusion Proteins